Based on AI driven macromolecular drug discovery, "Huashen Zhiyao" obtained nearly 500million yuan of round a financing

Huashen Zhiyao, a new drug development enterprise based on artificial intelligence technology （Helixon） Nearly completed 5 One hundred million yuan A Round of funding . This round of financing is led and invested by Wuyuan capital , Ficus altissima capital 、Neumann Capital And three angel investors Xianghe capital 、 Hillhead venture capital 、 Qingzhi Capital Co., Ltd . Huashen Zhiyao will continue to focus AI+ The field of new drug development , Team expansion and business development , perfect AI High performance computing power , Expand the high-throughput experimental platform , At the same time, we will promote independent research and development of pipelines and foreign cooperation .

Huashen Zhiyao technology （ Beijing ） The limited company was established in 2021 year 6 month , Focus on building a new generation of artificial intelligence scientific computing platform , Combined with self-developed high-throughput biological experimental technology , Provide micro world molecular computing for drug R & D personnel 、 Simulation and design of intelligent systems .